Kyverna Therapeutics, Inc.
KYTX
$7.66
-$0.19-2.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 22.65M | 30.01M | 137.19M | 135.93M | 127.43M |
| Gross Profit | -22.65M | -30.01M | -137.19M | -135.93M | -127.43M |
| SG&A Expenses | 37.43M | 36.11M | 34.40M | 35.70M | 33.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 163.79M | 169.83M | 171.59M | 171.63M | 160.65M |
| Operating Income | -163.79M | -169.83M | -171.59M | -171.63M | -160.65M |
| Income Before Tax | -156.40M | -161.31M | -160.99M | -158.70M | -145.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -156.40 | -161.31 | -160.99 | -158.70 | -145.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -156.40M | -161.31M | -160.99M | -158.70M | -145.42M |
| EBIT | -163.79M | -169.83M | -171.59M | -171.63M | -160.65M |
| EBITDA | -238.89M | -244.78M | -208.06M | -207.94M | -196.95M |
| EPS Basic | -3.28 | -3.66 | -3.72 | -3.67 | -3.37 |
| Normalized Basic EPS | -2.05 | -2.28 | -2.33 | -2.30 | -2.10 |
| EPS Diluted | -3.28 | -3.66 | -3.72 | -3.67 | -3.37 |
| Normalized Diluted EPS | -2.05 | -2.28 | -2.33 | -2.30 | -2.10 |
| Average Basic Shares Outstanding | 194.23M | 177.01M | 173.09M | 172.83M | 172.73M |
| Average Diluted Shares Outstanding | 194.23M | 177.01M | 173.09M | 172.83M | 172.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |